Biocon Corporate Presentation

Generics: Q1 FY22 Biocon KEY HIGHLIGHTS COVID-19 led operational and supply chain challenges in API manufacturing, expected to normalize in the coming quarter Gradual ramp-up of Tacrolimus in US while statins' market share was resilient Q1 FY22 Q 1 F Y 21 Revenue *621Cr *486Cr 22% YoY decrease Entered Labetalol and Esomeprazole in the US with estimated market size* of $63m and $230m, respectively Delay in site inspections, consequently launches, due to travel restrictions On track to commission greenfield Immunosuppressant API facility in Visakhapatnam in FY 2022 *US Market value based on IQVIA Profit Before Tax *29Cr *96Cr 6% of revenue 15% of revenue 11

View entire presentation